Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

SMC Update - March 2011 [updated]

The Scottish Medicines Consortium (SMC) has issued its monthly advice on new medicines.

Adapalene and benzoyl peroxide gel (Epiduo®) has been rejected for use in the cutaneous treatment of acne vulgaris when comedones, papules and pustules are present. The clinical and economic case did not consider comparative efficacy versus alternative treatments.

[Updated] To clarify, Epiduo® has been rejected for use in combination with an oral antibacterial in severe acne in individuals who are contraindicated to or refuse treatment with oral isotretinoin.

Exenatide (Byetta®) has been accepted for restricted use in the treatment of type 2 diabetes mellitus in combination with thiazolidinediones with or without metformin in patients who have not achieved adequate glycaemic control. The restriction is to use in combination with metformin and a thiazolidinedione as a third-line pre-insulin treatment option.

Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.

Share 'SMC Update - March 2011 [updated]' on Email Share 'SMC Update - March 2011 [updated]' on Delicious Share 'SMC Update - March 2011 [updated]' on Digg Share 'SMC Update - March 2011 [updated]' on Facebook Share 'SMC Update - March 2011 [updated]' on Google+ Share 'SMC Update - March 2011 [updated]' on reddit Share 'SMC Update - March 2011 [updated]' on StumbleUpon Share 'SMC Update - March 2011 [updated]' on Twitter

atomic-wealth

No Comments to “SMC Update - March 2011 [updated]”

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.
Akismet has protected Prescribing Advice for GPs from 789,208 spam comments.

atomic-wealth
fond-illness
summer